“Weight loss drugs could help people avoid getting addicted to alcohol, tobacco and drugs such as cannabis and cocaine, a study has found.

They could also reduce the risk of people already addicted to illicit substances having an overdose, ending up in hospital or dying, according to research published in the British Medical Journal.

Glucagon-like peptide-1 receptor agonists used to treat type 2 diabetes and obesity, such as Mounjaro and Ozempic, are thought to work by influencing the brain’s reward pathways in order to cut cravings. They help people feel fuller by mimicking the natural substance released after eating.

The US study analysed 606,434 US veterans with type 2 diabetes, who were monitored for up to three years. It found that GLP-1s reduced the risk of alcohol-related disorders in those with no history of substance use by 18% and of using cannabis (14%), cocaine (20%), nicotine (20%) and opioids (25%), compared with those on other sodium-glucose cotransporter-2 drugs also used to treat diabetes.

Weight loss drugs also reduce the risk of people already using substances from overdosing (39%), needing emergency help in A&E (31%) or dying (50%).”

From The Guardian.